Diabetic RetinaScreen, National Screening Service, Health Service Executive, Dublin, Ireland.
Mater Retinal Research Group, Mater Misericordiae University Hospital, Dublin, Ireland.
Br J Ophthalmol. 2022 Mar;106(3):409-414. doi: 10.1136/bjophthalmol-2020-317508. Epub 2020 Dec 17.
To study the uptake of annual diabetic retinopathy screening and study the 5-year trends in the detection of screen-positive diabetic retinopathy and non-diabetes-related eye disease in a cohort of annually screened individuals.
Retrospective retinopathy screening attendance and retinopathy grading analysis.
Community-based retinopathy screening centres for the Diabetic RetinaScreen Programme.
171 557 were identified by the screening programme to be eligible for annual diabetic retinopathy screening. 120 048 individuals over the age of 12 consented to and attended at least one screening appointment between February 2013 to December 2018.
Detection rate per 100 000 of any retinopathy, screen-positive referrable retinopathy and nondiabetic eye disease.
Uptake of screening had reached 67.2% in the fifth round of screening. Detection rate of screen-positive retinopathy reduced from 13 229 to 4237 per 100 000 screened over five rounds. Detection of proliferative disease had reduced from 2898 to 713 per 100 000 screened. Non-diabetic eye disease detection and referral to treatment centres increased almost eightfold from 393 in round 1 to 3225 per 100 000 screened. The majority of individuals referred to treatment centres for ophthalmologist assessment are over the age of 50 years.
Screening programme has seen a reduced detection rate both screen-positive retinopathy referral in Ireland over five rounds of screening. Management of nondiabetic eye diseases poses a significant challenge in improving visual outcomes of people living with diabetes in Ireland.
研究年度糖尿病视网膜病变筛查的接受情况,并研究在每年筛查的队列中筛查阳性糖尿病视网膜病变和非糖尿病相关眼病的 5 年趋势。
回顾性视网膜病变筛查参与和视网膜病变分级分析。
糖尿病视网膜病变筛查计划的基于社区的视网膜病变筛查中心。
通过筛查计划确定 171557 人符合年度糖尿病视网膜病变筛查条件。在 2013 年 2 月至 2018 年 12 月期间,年龄在 12 岁以上的 120048 人同意并至少参加了一次筛查预约。
每 10 万人中任何视网膜病变、筛查阳性可转诊的视网膜病变和非糖尿病眼病的检出率。
第五轮筛查的筛查参与率已达到 67.2%。在五轮筛查中,筛查阳性视网膜病变的检出率从每 10 万人 13229 例降至 4237 例。增殖性疾病的检出率从每 10 万人 2898 例降至 713 例。非糖尿病眼病的检出率和转诊至治疗中心的比例从第一轮的 393 例增加到每 10 万人 3225 例,几乎增加了 8 倍。转诊至治疗中心进行眼科评估的大多数人年龄在 50 岁以上。
在五轮筛查中,爱尔兰的筛查计划都观察到筛查阳性视网膜病变转诊的检出率有所下降。管理非糖尿病眼病对改善爱尔兰糖尿病患者的视力预后构成了重大挑战。